Thomas Trimarchi is President & CFO at BridgeBio Pharma, Inc. (BBIO). They have made 2 open-market trades across 1 company since 2025, most recently 2026-08-16.
CIK 0002030813
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BBIO | 336,529 | $22.3M |
Shares reported on the most recent Form 4, priced at the 2026-08-18 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BBIO | SELL · 10b5-1 | 2026-05-18 | 2026-05-19 | $65.08 | $888K | -2.4% | -1.2% | +19.2% |
| BBIO | SELL | 2026-02-17 | 2026-02-18 | $74.72 | $1.0M | -10.7% | -6.6% | -10.0% |
| BBIO | SELL · 10b5-1 | 2025-11-17 | 2025-11-18 | $66.46 | $2.3M | +9.5% | +13.1% | +15.7% |
| BBIO | SELL | 2025-08-21 | 2025-08-22 | $49.48 | $4.2M | +6.3% | +5.7% | +32.5% |
| BBIO | SELL · 10b5-1 | 2025-08-18 | 2025-08-19 | $50.23 | $1.7M | +5.8% | +9.1% | +36.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.